Elijah Hall, BS

Kate Orland, MS, CGC

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population​

  • Summarize Hypertrophic Cardiomyopathy (HOCM) pathophysiology related to the mechanism of action of Mavacamten​.
  • Examine the research findings from a study on Mavacamten in a diverse population​.
  • Identify the roles of genetic counselors in the space of inherited cardiovascular conditions.

 

Session date: 
03/12/2025 - 4:00pm to 5:00pm CDT
Location: 
Virtually
WI 53705
United States
See map: Google Maps
  • 1.00 AAPA Category 1 CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 CDR CPEUs
  • 1.00 NSGC Category 1 CEU Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Elijah Hall, BS (grad student)
Kate Orland, MS, CGC